Webb22 feb. 2024 · Investors Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. Corporate Presentation The following is an investor update, effective January 2024, presented by Robert Bitterman. Mr. Webb2 maj 2024 · Phio Pharmaceuticals Corp. announced that its Board of Directors has appointed Patricia A. Bradford as an independent director of the Company.... April 3, 2024
Phio Pharmaceuticals Contact Us
WebbPHIO Phio Pharmaceuticals Corp (NASDAQ:PHIO) was one of the biggest winners on Friday as the stock closed up $1.44 on the day with huge volumes. I alerted it when it was trading at 75c as a potential big mover due to its huge cash position and catalyst and it did not disappoint us. WebbPhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update. Additional Formats. PDF Version. February 22, 2024. the prestige sinhala sub
PHIO Stock Message Board Phio Pharmaceuticals Corp.
Webb3 apr. 2024 · Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its … Webb11 aug. 2024 · The trading in this stock has been some of the worse criminal manipulation that I have ever seen, with the SOB's never letting it run,always keeping it pined within a ten cents move, total manipulation, if some kind of big news was to hit, it could blow up the corrupted naked shorters up badly. WebbPhio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market. PR Newswire. Jan-25-21 05:14PM. Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market. sight advice